RecruitingEarly Phase 1NCT06785519

CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

Sponsor

He Huang

Enrollment

9 participants

Start Date

Jan 31, 2025

Study Type

INTERVENTIONAL

Conditions

Lupus Nephritis

Summary

A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection for people with lupus nephritis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.